RE:RE:RE:BTD is slow process. By the way, if the FDA suggested Theralase submit the 18 month CR rate of Ruvidar PDT in order to demonstrate a superior durable response to available treatments then we are looking pretty good.
At 18 months Adstiladrin's CR rate was down to 13% And Adstiladrin is the best available treatment with FDA approval.. As DJDawg often points out, once one of our patients has achieved a CR at every assessment up to 360 days they have always maintained that CR at 450 days. So we could be looking at comparative 18 month durable responses of:
Adstiladri 13%
Ruvidar 37% I'd certainly call this a substantial improvement over available therapy!
DJDawg wrote:
Thanks Eog. It's good to talk it out. Your reasoning sounds good. I just wish that TLT would be more open about it as things are so vague and slow.